MALVERN, Pa., April 14, 2016 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2016 earnings on Tuesday, April 26, 2016 at 4:00 PM Eastern Time.
The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, April 26, 2016. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com. If you are unable to participate during the live webcast, an archive will be available on our website for two weeks.
About BioTelemetry
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.gobio.com.
Contact: BioTelemetry, Inc. Heather C. Getz Investor Relations 800-908-7103 [email protected]


Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Italy Fines Apple €98.6 Million Over App Store Dominance
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 



